No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CNS Cohen & Steers
- 81.470
- -0.370-0.45%
Trading Jul 22 11:48 ET
4.12BMarket Cap31.95P/E (TTM)
82.130High80.250Low57.86KVolume81.895Open81.840Pre Close4.68MTurnover0.22%Turnover Ratio31.33P/E (Static)50.54MShares85.95052wk High10.87P/B2.20BFloat Cap48.72152wk Low2.32Dividend TTM26.96MShs Float92.060Historical High2.85%Div YieldTTM2.30%Amplitude3.421Historical Low80.879Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Some Confidence Is Lacking In Cohen & Steers, Inc.'s (NYSE:CNS) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may consider Cohen & Steers, Inc. (NYSE:CNS) as a stock to avoid entirely with its 32.5
Express News | Cohen & Steers Inc : Evercore ISI Raises Target Price to $85 From $75
Earnings Call Summary | Cohen & Steers(CNS.US) Q2 2024 Earnings Conference
The following is a summary of the Cohen & Steers, Inc. (CNS) Q2 2024 Earnings Call Transcript:Financial Performance:Cohen & Steers reported Q2 2024 earnings per share of $0.68, a slight decrease
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
Cohen & Steers Reports Q2 Adjusted Earnings of $0.68 a Share Vs. Street Estimate of $0.67
04:21 PM EDT, 07/17/2024 (MT Newswires) -- Cohen & Steers Reports Q2 Adjusted Earnings of $0.68 a Share vs. Street Estimate of $0.67Price: 81.29, Change: -0.05, Percent Change: -0.06
Cohen & Steers Reports Q2 Revenue of $121.7 Million Vs. Street Estimate of $122.5 Million
04:20 PM EDT, 07/17/2024 (MT Newswires) -- Cohen & Steers Reports Q2 Revenue of $121.7 Million vs. Street Estimate of $122.5 MillionPrice: 81.29, Change: -0.05, Percent Change: -0.06
Comments
2
Wednesday 7/17/24 Earnings Calls. I tagged a few, not all. 📊⚡️📊
$Tesla(TSLA.US$ $ASML Holding(ASML.US$ $First Bancorp(FNLC.US$ $Old Second Bancorp(OSBC.US$ $Kinder Morgan(KMI.US$ $Johnson & Johnson(JNJ.US$ $Netflix(NFLX.US$ $Monarch Casino & Resort(MCRI.US$ $Anew Medical(WENA.US$ $Cohen & Steers(CNS.US$ $SL Green Realty(SLG.US$ $Monarch Casino & Resort(MCRI.US$ $First Industrial Realty Trust Inc(FR.US$ $Alcoa(AA.US$ $Las Vegas Sands(LVS.US$ $Canfor Pulp Products Inc(CFX.CA$
$Tesla(TSLA.US$ $ASML Holding(ASML.US$ $First Bancorp(FNLC.US$ $Old Second Bancorp(OSBC.US$ $Kinder Morgan(KMI.US$ $Johnson & Johnson(JNJ.US$ $Netflix(NFLX.US$ $Monarch Casino & Resort(MCRI.US$ $Anew Medical(WENA.US$ $Cohen & Steers(CNS.US$ $SL Green Realty(SLG.US$ $Monarch Casino & Resort(MCRI.US$ $First Industrial Realty Trust Inc(FR.US$ $Alcoa(AA.US$ $Las Vegas Sands(LVS.US$ $Canfor Pulp Products Inc(CFX.CA$
+2
3
1
Investor concerns grow over Cohen & Steers' high P/E ratio in relation to dwindling earnings and low predicted growth rate. Speculations suggest the excessive P/E ratio is driven by investor confidence in a business turnaround which may not be sustainable given current earnings and growth rates.
An insider selling shares at a price lower than market value could reflect their belief in a fair lower price. Absence of purchases in the past year despite high insider ownership might cause concern. Usually, however, a high level of insider ownership is seen positively as it implies management's alignment with shareholder interests.
Gapping up
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg